All In MedTech

Device Trial Radar · NCT02158078

A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

A Prospective, Single Center, Post-Market Observational Study to Assess the Efficacy, Safety, and Patient Reported Outcomes of Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Jul 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

8

Actual

Start

Jun 2014

Primary completion

Nov 2014

Study completion Nov 2014

Sponsor

Lead sponsor
CeQur CorporationNot on our public-company list
Sponsor type
Industry
First posted
Jun 6, 2014

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • PaQ® Insulin Delivery DeviceDevice

    PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood) from baseline at Week 12Time frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University of Graz

    Graz, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.